Serum and Saliva Level of miR-31-5p and miR-let 7a in EBV Associated Oropharyngeal Cancer.
EBV
miR-31-5p
miR-let 7a
oropharyngeal cancer
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
26 Jul 2023
26 Jul 2023
Historique:
received:
10
07
2023
revised:
23
07
2023
accepted:
25
07
2023
medline:
12
8
2023
pubmed:
12
8
2023
entrez:
12
8
2023
Statut:
epublish
Résumé
Epstein-Barr virus (EBV) has a well-documented association with head and neck neoplasms, including nasopharyngeal carcinoma (NPC). In the last few years, research aimed at elucidating the role of the miRs in the pathogenesis of head and neck cancer (HNC) has gained importance. The study of miRs expression has set new directions in the search for biomarkers with diagnostic and prognostic value, and even in the search for new therapeutic targets for various tumors, including HNC. The aim of current study was to approximate the importance of miR-31-5p and miR-let 7a in the pathogenesis of EBV associated oropharyngeal cancer. For this purpose, experiments were carried out to determine the level of mentioned miRs in serum among patients diagnosed with oropharyngeal cancer linked to EBV infection, depending on histological differentiation-grading (G1-G3) and TNM classification. All clinical specimens stratified by HPV status were HPV negative. The level of antibodies EBNA and EBVCA was also assessed. The obtained results showed a significantly increased serum level of miR-31-5p but decreased level of miR-let 7a in EBV positive oropharyngeal cancer patients. We demonstrated association between the level of tested miRs and clinical stage. Our findings showed that miR-31-5p and miR-let-7a may be involved in development and progression of EBV associated oropharyngeal cancer. Therefore, it seems important to further study these molecules, as well as to determine whether they could be important biomarkers in the diagnosis of oropharyngeal cancer associated with EBV infection.
Identifiants
pubmed: 37569339
pii: ijms241511965
doi: 10.3390/ijms241511965
pmc: PMC10418762
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Sci Rep. 2022 Jun 27;12(1):10875
pubmed: 35760845
Virology. 2008 Dec 20;382(2):257-66
pubmed: 18950829
Microorganisms. 2019 Jun 24;7(6):
pubmed: 31238570
Mol Ther Nucleic Acids. 2019 Sep 6;17:657-668
pubmed: 31400608
Genes (Basel). 2022 Mar 26;13(4):
pubmed: 35456400
Endocr Relat Cancer. 2010 Jan 29;17(1):F19-36
pubmed: 19779035
Cancer Biomark. 2016;16(1):55-64
pubmed: 26484611
Int J Mol Sci. 2022 Jul 26;23(15):
pubmed: 35897831
J Cancer. 2020 Feb 3;11(8):2091-2100
pubmed: 32127936
J Oral Pathol Med. 2015 Jan;44(1):28-36
pubmed: 25040496
Int J Mol Sci. 2018 Apr 17;19(4):
pubmed: 29673190
Science. 2004 Apr 30;304(5671):734-6
pubmed: 15118162
Med Hypotheses. 2009 Aug;73(2):184-6
pubmed: 19361933
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
Mol Cancer. 2019 Mar 30;18(1):63
pubmed: 30927923
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Head Neck. 2012 Feb;34(2):219-24
pubmed: 22083872
PLoS Pathog. 2011 Aug;7(8):e1002193
pubmed: 21901094
Front Oncol. 2020 May 12;10:619
pubmed: 32547936
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Oncol Rep. 2021 Jan;45(1):58-64
pubmed: 33200230
J Pathol. 2015 Jan;235(2):323-33
pubmed: 25251730
PLoS Pathog. 2006 Mar;2(3):e23
pubmed: 16557291
Anticancer Res. 2012 Oct;32(10):4201-12
pubmed: 23060540
PLoS One. 2010 Sep 20;5(9):
pubmed: 20862214
Eur J Oral Sci. 2018 Oct;126 Suppl 1:49-66
pubmed: 30178562
J Cell Physiol. 2017 Aug;232(8):2178-2185
pubmed: 27935034
Cancer Immunol Immunother. 2020 Aug;69(8):1615-1626
pubmed: 32314041
Mol Ther Nucleic Acids. 2019 Jun 7;16:471-480
pubmed: 31051332
Cell Cycle. 2020 Aug;19(15):1983-1993
pubmed: 32594835
J Virol. 2015 Nov;89(22):11256-68
pubmed: 26311882
J Virol. 2007 Jan;81(2):1033-6
pubmed: 17079300
Neoplasma. 2019 Sep;66(5):825-829
pubmed: 31129965
Br Dent J. 2022 Nov;233(9):780-786
pubmed: 36369568
Oncol Rep. 2012 May;27(5):1660-8
pubmed: 22322403
Oral Dis. 2021 Jan;27(1):73-93
pubmed: 32569410
Eur Arch Otorhinolaryngol. 2020 Sep;277(9):2407-2412
pubmed: 32342197
Biomed Pharmacother. 2018 Dec;108:1162-1169
pubmed: 30372817
Oral Dis. 2015 Sep;21(6):685-93
pubmed: 25809224
Nat Commun. 2015 Jul 02;6:7353
pubmed: 26135619
Sci Rep. 2018 Jan 12;8(1):675
pubmed: 29330429
Infect Agent Cancer. 2020 Jun 23;15:42
pubmed: 32582365
Lancet Infect Dis. 2019 Feb;19(2):131-132
pubmed: 30722999
Anticancer Res. 2015 Mar;35(3):1657-61
pubmed: 25750324
Cell Death Discov. 2022 Mar 29;8(1):140
pubmed: 35351880
Curr Opin Virol. 2013 Jun;3(3):227-32
pubmed: 23683686
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Theranostics. 2019 Jan 25;9(4):920-931
pubmed: 30867806
Cancers (Basel). 2022 Dec 31;15(1):
pubmed: 36612284
Cells. 2020 Jan 23;9(2):
pubmed: 31979244
Carcinogenesis. 2017 May 1;38(5):485-491
pubmed: 28449079
Microrna. 2012;1(1):34-9
pubmed: 25048088
Cancers (Basel). 2021 Jan 25;13(3):
pubmed: 33504017
Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11400-5
pubmed: 17600087
Infect Agent Cancer. 2013 Feb 02;8(1):7
pubmed: 23374258
Pathogens. 2022 Feb 09;11(2):
pubmed: 35215172
Int J Oral Sci. 2021 Aug 2;13(1):24
pubmed: 34341329
Clin Lab. 2017 Nov 1;63(11):1771-1776
pubmed: 29226639
Nucleic Acids Res. 2011 Mar;39(5):1880-93
pubmed: 21062812
Mol Cancer. 2016 Apr 07;15:28
pubmed: 27056547
Int J Mol Sci. 2022 Feb 22;23(5):
pubmed: 35269544
J Virol. 2014 Oct;88(19):11166-77
pubmed: 25031339